DK1940461T3 - Samtidig kemoterapi og immunterapi - Google Patents

Samtidig kemoterapi og immunterapi

Info

Publication number
DK1940461T3
DK1940461T3 DK06836816T DK06836816T DK1940461T3 DK 1940461 T3 DK1940461 T3 DK 1940461T3 DK 06836816 T DK06836816 T DK 06836816T DK 06836816 T DK06836816 T DK 06836816T DK 1940461 T3 DK1940461 T3 DK 1940461T3
Authority
DK
Denmark
Prior art keywords
immunotherapy
concurrent chemotherapy
chemotherapy
concurrent
Prior art date
Application number
DK06836816T
Other languages
English (en)
Inventor
John H Sampson
Darell D Bigner
Amy Heimberger
Duane Mitchell
Original Assignee
Univ Duke
Univ Texas M D Anderson Cancer Ct
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Duke, Univ Texas M D Anderson Cancer Ct filed Critical Univ Duke
Application granted granted Critical
Publication of DK1940461T3 publication Critical patent/DK1940461T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK06836816T 2005-11-02 2006-11-02 Samtidig kemoterapi og immunterapi DK1940461T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73274105P 2005-11-02 2005-11-02
PCT/US2006/042812 WO2007056061A2 (en) 2005-11-02 2006-11-02 Concurrent chemotherapy and immunotherapy

Publications (1)

Publication Number Publication Date
DK1940461T3 true DK1940461T3 (da) 2014-03-31

Family

ID=38023803

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06836816T DK1940461T3 (da) 2005-11-02 2006-11-02 Samtidig kemoterapi og immunterapi

Country Status (16)

Country Link
US (3) US9399662B2 (da)
EP (1) EP1940461B1 (da)
JP (2) JP5674273B2 (da)
KR (1) KR101399591B1 (da)
CN (3) CN104857500A (da)
AU (1) AU2006312013B2 (da)
BR (1) BRPI0618050A2 (da)
CA (1) CA2628282C (da)
DK (1) DK1940461T3 (da)
ES (1) ES2454990T3 (da)
IL (1) IL191158A (da)
MX (1) MX2008005640A (da)
NZ (1) NZ567837A (da)
RU (1) RU2473560C2 (da)
WO (1) WO2007056061A2 (da)
ZA (1) ZA200803759B (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8900816B2 (en) * 2007-07-19 2014-12-02 Duke University Assay for anti-EGFRvIII antibodies
US20110135637A1 (en) * 2009-11-16 2011-06-09 Duke University Trimodal cancer therapy
US9529689B2 (en) 2009-11-30 2016-12-27 Red Hat, Inc. Monitoring cloud computing environments
SE535982C2 (sv) * 2009-12-15 2013-03-19 Theravac Pharmaceuticals Ab Ett nytt vaccin som angriper tumörkärl som ett effektivt redskap i tumörterapi
SG181628A1 (en) * 2009-12-22 2012-07-30 Celldex Therapeutics Inc Vaccine compositions
WO2012003810A1 (zh) * 2010-07-09 2012-01-12 中国科学院上海巴斯德研究所 Foxp3及调节性ｔ细胞的调节因子及其应用
DK2640842T3 (da) * 2010-11-17 2018-08-13 Aduro Biotech Inc Fremgangsmåder og sammensætninger til inducering af en immunreaktion på EGFRVIII
TWI386203B (zh) * 2011-01-07 2013-02-21 Univ China Medical 治療腦癌或用以降低腦癌細胞對替莫唑胺之抗藥性之醫藥組合物及其應用
JP6224597B2 (ja) * 2011-09-27 2017-11-01 バイオメッド バレー ディスカバリーズ，インコーポレイティド グリオーマを処置するための組成物及び方法
GB2523211B (en) 2012-01-27 2020-03-18 Univ Jefferson MCT protein inhibitor-related prognostic and therapeutic methods
CN104780938A (zh) 2012-08-02 2015-07-15 小利兰·斯坦福大学托管委员会 用于肿瘤治疗的基于EGFRvIII序列的肽疫苗
EP2986290A4 (en) 2013-04-19 2017-01-04 Thomas Jefferson University Caveolin-1 related methods for treating glioblastoma with temozolomide
RU2725135C1 (ru) * 2019-11-19 2020-06-30 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Гемопротекторное средство
EP4069253A4 (en) * 2019-12-02 2024-01-10 Phoenix Biotechnology, Inc. METHOD AND COMPOSITIONS FOR TREATING GLIOBLASTOMA
JP2023550148A (ja) 2020-11-20 2023-11-30 シンシア・イノベーション・インコーポレイテッド がん免疫治療に用いられる武装二重ｃａｒ－ｔ組成物及び方法
JP2025518289A (ja) * 2022-06-03 2025-06-12 ブルーロック セラピューティクス エルピー 細胞送達媒体及びそれを使用する方法
CN115887450B (zh) * 2022-12-09 2024-06-25 杭州师范大学 角鲨烯化替莫唑胺的合成及其自组装纳米粒的制备和应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2261433A1 (en) 1993-12-09 1995-06-10 Belinda Sanchez Ramirez Composition comprising autologous epidermal growth factor
ATE262586T1 (de) * 1994-11-28 2004-04-15 Univ Jefferson Fusion junction typ iii mutant egf rezeptor peptid-tumorvakzin
US6503503B1 (en) 1997-05-13 2003-01-07 Duke University Allogeneic cellular vaccine
US5891432A (en) 1997-07-29 1999-04-06 The Immune Response Corporation Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
US6645503B1 (en) 1998-03-10 2003-11-11 Wyeth Holdings Corporation Antigenic conjugates of conserved lipopolysaccharides of gram negative bacteria
DE19842415A1 (de) * 1998-09-16 2000-03-23 Merck Patent Gmbh Pharmazeutische Zubereitung
US6251886B1 (en) * 1998-12-07 2001-06-26 Schering Corporation Methods of using temozolomide in the treatment of cancers
WO2001022972A2 (en) * 1999-09-25 2001-04-05 University Of Iowa Research Foundation Immunostimulatory nucleic acids
EP1349934A2 (en) * 2000-11-20 2003-10-08 Diadexus, Inc. Compositions and methods relating to breast specific genes and proteins
US20020128228A1 (en) * 2000-12-01 2002-09-12 Wen-Jen Hwu Compositions and methods for the treatment of cancer
WO2002060484A1 (en) 2001-01-31 2002-08-08 Idec Pharmaceuticals Corporation Use of cd23 antagonists for the treatment of neoplastic disorders
CA2479528A1 (en) * 2002-03-25 2003-10-02 Technologies Biolactis Inc. Chemotherapeutic agents as anti-cancer vaccine adjuvants and therapeutic methods thereof
CA2480099C (en) * 2002-03-26 2019-01-08 Zensun (Shanghai) Sci-Tech. Ltd. Erbb3 based methods and compositions for treating neoplasms
US20060147420A1 (en) * 2004-03-10 2006-07-06 Juan Fueyo Oncolytic adenovirus armed with therapeutic genes
GB0221574D0 (en) 2002-09-17 2002-10-23 Isis Innovation Treatments
US20040147428A1 (en) * 2002-11-15 2004-07-29 Pluenneke John D. Methods of treatment using an inhibitor of epidermal growth factor receptor
EP1676132B1 (en) * 2003-10-21 2014-01-22 Cedars-Sinai Medical Center Combination of chemotherapy and administration of glioma-antigen-pulsed dendritic cells in the treatment of glioma
US20050215501A1 (en) * 2003-10-24 2005-09-29 Coley Pharmaceutical Group, Inc. Methods and products for enhancing epitope spreading
SG149013A1 (en) * 2003-12-17 2009-01-29 Wyeth Corp Immunogenic peptide carrier conjugates and methods of producing same
US7767792B2 (en) 2004-02-20 2010-08-03 Ludwig Institute For Cancer Research Ltd. Antibodies to EGF receptor epitope peptides

Also Published As

Publication number Publication date
ZA200803759B (en) 2009-10-28
KR101399591B1 (ko) 2014-06-18
NZ567837A (en) 2011-11-25
RU2008120665A (ru) 2009-11-27
AU2006312013A8 (en) 2008-06-19
IL191158A (en) 2015-08-31
AU2006312013B2 (en) 2012-10-04
AU2006312013A1 (en) 2007-05-18
JP5674273B2 (ja) 2015-02-25
WO2007056061A3 (en) 2009-05-07
EP1940461A4 (en) 2009-12-09
US20090220551A1 (en) 2009-09-03
CA2628282C (en) 2015-04-07
US9399662B2 (en) 2016-07-26
US20150118181A1 (en) 2015-04-30
CN101594877A (zh) 2009-12-02
EP1940461B1 (en) 2014-01-08
MX2008005640A (es) 2008-12-09
KR20080091427A (ko) 2008-10-13
CN103463630A (zh) 2013-12-25
CN104857500A (zh) 2015-08-26
RU2473560C2 (ru) 2013-01-27
JP2013126994A (ja) 2013-06-27
US20180215789A1 (en) 2018-08-02
JP2009518287A (ja) 2009-05-07
JP5746721B2 (ja) 2015-07-08
BRPI0618050A2 (pt) 2011-08-16
IL191158A0 (en) 2008-12-29
CA2628282A1 (en) 2007-05-18
WO2007056061A2 (en) 2007-05-18
ES2454990T3 (es) 2014-04-14
EP1940461A2 (en) 2008-07-09

Similar Documents

Publication Publication Date Title
IL191158A0 (en) Concurrent chemotherapy and immunotherapy
DK2118140T3 (da) Humancytomegalovirus-neutraliserende antistoffer og anvendelse deraf
DK2059535T3 (da) Prlr-specifikt antistof og anvendelser deraf
DK2209806T3 (da) Anti-hepcidin-antistoffer og anvendelser deraf
DK1994055T3 (da) Anti-5t4-antistoffer og anvendelser deraf
DK2907827T3 (da) Humaniserede anti-faktor D-antistoffer og anvendelser deraf
PL1850873T3 (pl) Przeciwciała przeciwko tgfbeta
DK1934179T3 (da) Fremgangsmåder og mellemprodukter
DE602006000573D1 (de) Gleitelement
DK2574640T3 (da) Bindemidler og dermed fremstillede materialer
PT1920065T (pt) Anticorpos anti-alfavbeta6 e suas utilizações
DK1988307T3 (da) Reduktionsgear
ITBO20050495A1 (it) Elettrocatetere esogageo
DK2170827T3 (da) Indolin-2-oner og aza-indolin-2-oner
DK1871418T3 (da) Humaniserede anti-cd70-bindende midler og anvendelser deraf
DK1969391T3 (da) Tyndfilm emitter-absorber indretning og fremgangsmåde
DE602005014129D1 (de) Rohrleitung
DK2001556T3 (da) Thioninium-forbindelser og anvendelse deraf
DK2176284T3 (da) Lantibiotika og anvendelser deraf
DK1976884T3 (da) Anti-ephrinb2-antistoffer og fremgangsmåder til anvendelse deraf.
DK1957050T3 (da) Polypeptidfilm og fremgangsmåder
DK1921086T3 (da) Antitumormiddel
EP1909047A4 (en) REFRIGERATION DEVICE
FI20051053L (fi) Jäähdytin
EP1961959A4 (en) COMPRESSOR